Luye Pharma Group Valuation

Q: What is the Fair Price of LYPH.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

LYPH.F ($0.38) is trading below our estimate of [[future cash flow value]] ($2.02)

Is LYPH.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Future Cash Flow Value
Significantly Below Future Cash Flow Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of LYPH.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: LYPH.F ($0.38) is trading below our estimate of future cash flow value ($2.02)

Significantly Below Future Cash Flow Value: LYPH.F is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LYPH.F?

Key metric: As LYPH.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LYPH.F. This is calculated by dividing LYPH.F's market cap by their current earnings.
What is LYPH.F's PE Ratio?
PE Ratio	21.4x
Earnings	CN¥396.94m
Market Cap	CN¥8.48b

LYPH.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.1x
Enterprise Value/EBITDA	6.7x
PEG Ratio	0.7x

Price to Earnings Ratio vs Peers

How does LYPH.F's PE Ratio compare to its peers?

The above table shows the PE ratio for LYPH.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	40.8x
PCRX Pacira BioSciences	129.9x	31.41%	US$891.6m
OGN Organon	8.7x	34.41%	US$1.6b
COLL Collegium Pharmaceutical	18.3x	28.93%	US$1.1b
INVA Innoviva	6x	-2.95%	US$1.6b
LYPH.F Luye Pharma Group	21.4x	32.36%	US$9.7b

Price-To-Earnings vs Peers: LYPH.F is good value based on its Price-To-Earnings Ratio (21.4x) compared to the peer average (40.8x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does LYPH.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

5 Companies	Price / Earnings	Estimated Growth	Market Cap
NDOI Endo	0.3x	n/a	US$1.76b
BTMD biote	1.6x	-77.82%	US$48.87m
OWPC One World Products	0.2x	n/a	US$1.17m
KOAN Resonate Blends	0.4x	n/a	US$466.56k

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: LYPH.F is expensive based on its Price-To-Earnings Ratio (21.4x) compared to the US Pharmaceuticals industry average (17.6x).

Price to Earnings Ratio vs Fair Ratio

What is LYPH.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LYPH.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	21.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LYPH.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystPriceTarget

Community Contributor

US$0.64

Fair Value

40.9% undervalued

Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/19 16:35
End of Day Share Price	2026/01/09 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Luye Pharma Group Ltd. is covered by 18 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jessica Li	BofA Global Research
Lok Kwan Chiu	CCB International Securities Limited
Ling Zhang	China Merchants Securities (HK) Co., Ltd